Dr. Hulme joined Sophiris in April 2011 and brings over 20 years of drug development experience.. She most recently served as Executive Vice President and Head of Global Development at Elan Pharmaceuticals, and has a proven track record in all phases of global clinical drug development. Dr. Hulme joined Elan Corp. Plc. in October 1995 and served. as an Executive Vice President since January 2005. She has achieved multiple regulatory approvals in the United States and Europe, coupled with hands on global commercial launch experience for the blockbuster drug Tysabri.. Dr. Hulme held several positions in Clinical Research at Glaxo Wellcome Pharmaceuticals (United Kingdom) and served as Lecturer at Luton University. Dr. Hulme holds a first class honors Degree in Science from Luton University and earned her Ph.D. from Cranfield Institute of Technology.
